Related Experiment Video
Updated: Mar 10, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Actein enhances TRAIL effects on suppressing gastric cancer progression by activating p53/Caspase-3 signaling
1Huaihe Hospital of Henan University, Southern Institute of Huaihe Hospital of Henan University, No. 8 Hubei Road, 475000 Henan, China.
Abstract:
Actein (ACT), isolated from the rthizomes of Cimicifuga foetida, is a triterpene glycoside, showing inhibitory role in breast cancer cells. However, the effects of ACT treatment on gastric cancer have little been known. Thus, the study is conducted to explore the in vitro and in vivo role of ACT in gastric cancer. And the interactions between ACT and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were investigated in gastric cancer cells. A synergistic effect of ACT and TRAIL combination on apoptosis induction in gastric cancer cells was observed. The cancer cells were insensitive to TRAIL single therapy. However, gastric cancer cells receiving ACT were sensitive to TRAIL-triggered apoptotic response by enhancing Caspases cleavage, due to elevation of decoy receptor 1 and 2 (DcR1 and DcR2) dependent on p53. Bcl-2 family members of Bcl-2 and Mcl-1, belonging to anti-apoptosis, were decreased, whereas Bad and Bak, as pro-apoptotic members, were increased for ACT and TRAIL combined treatment. Additionally, the mouse xenograft model suggested that ACT and TRAIL in combination markedly inhibited gastric cancer growth in comparison to ACT or TRAIL monotherapy without toxicity. The present study revealed a dramatically therapeutic strategy for promoting TRAIL-induced anti-cancer effects on gastric cancer cells via ACT combination.
Insights
Actein (ACT) enhances TRAIL therapy for gastric cancer. Combining ACT with TRAIL synergistically induces apoptosis and inhibits tumor growth without toxicity, offering a new therapeutic strategy.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Actein (ACT), a triterpene glycoside from Cimicifuga foetida, shows promise in breast cancer.
- The therapeutic potential of ACT in gastric cancer remains largely unexplored.
Purpose of the Study:
- To investigate the in vitro and in vivo effects of ACT on gastric cancer.
- To explore the synergistic interaction between ACT and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in gastric cancer cells.
Main Methods:
- In vitro assays to assess apoptosis induction and protein expression.
- In vivo mouse xenograft model to evaluate tumor growth inhibition.
- Analysis of apoptosis-related proteins, including Caspases, Bcl-2 family members, and decoy receptors.
Main Results:
- Gastric cancer cells were insensitive to TRAIL monotherapy but sensitive when combined with ACT.
- ACT sensitized cells to TRAIL by upregulating decoy receptors (DcR1 and DcR2) dependent on p53, enhancing Caspase cleavage.
- Combined ACT and TRAIL treatment decreased anti-apoptotic proteins (Bcl-2, Mcl-1) and increased pro-apoptotic proteins (Bad, Bak).
- In vivo, combination therapy significantly inhibited gastric cancer growth without observed toxicity.
Conclusions:
- ACT acts synergistically with TRAIL to induce apoptosis and inhibit gastric cancer growth.
- This combination therapy represents a promising strategy for gastric cancer treatment by enhancing TRAIL-induced anti-cancer effects.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
Caspases

